- Protocol Short Name and Number: Alliance A051301/BMT CTN1201 DLBCL
- Protocol Long Name: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
- For access to Protocol documents please visit the CTSU site: https://www.ctsu.org
- Key Personnel
- BMT CTN # 1201 Protocol Chair: Charalambos Babis Andreadis, MD, MSCz (Alliance)
- BMT CTN # 1201 Protocol Chair: Timothy Fenske, MD (BMT CTN)
- BMT CTN # 1201 Protocol Coordinator: Destin Carlisle: dcarlisle@bsd.uchicago.edu
- Keywords: Ibrutinib, Autologous Transplant, Auto Transplant, Auto, Large B-Cell Lymphoma, Lymphoma, DLBCL, Alliance, A051301
For the Alliance A051301/BMT CTN 1201 study, centers participate via their NCTN group. The protocol may be accessed through the CTSU website: https://www.ctsu.org. For questions, contact the CTSU Help Desk: ctsucontact@westat.com or 1-888-823-5923.
To participate, follow the NCTN activation process. Contact Alliance protocol coordinator, Destin Carlisle, at dcarlisle@uchicago.edu for more information.